OBJECTIVE: The present work is designed to synthesise some isomeric new series of Quinazoline-4-one/4-thione derivatives, based on the pharmacophoric model of central nervous system (CNS) activity by structural modifications retaining the essential structural features for the activity and evaluated for their anticonvulsant and CNS depressant activities.

METHODS: A series of 7-chloro-3-[substituted (amino/phenylamino)]-2-phenyl quinazolin-4 (3H)-one/thione derivatives and 1-[7-chloro-4-oxo-2-phenylquinoxaline-3 (4H-y)] substituted urea derivatives were prepared. The reaction scheme proceeds through the intermediate 7-chloro-2-phenyl-4H-benzo[d] [1, 3] oxazin-4-one. The structures of the newly synthesised compounds were characterized from infrared (IR), 1H nuclear magnetic resonance (NMR) and mass spectra (m/z) and elemental analysis. The anti-convulsant and CNS depressant activity were investigated by maximum electroshock (MES) seizure test and porsolt's behavioural despair test (forced swimming) respectively. The rota-rod test was performed to assess any probable changes in motor coordination induced by the test compounds.

RESULTS: The physicochemical and spectroscopic data clearly confirmed the synthesis of quinazoline derivatives with a common skeleton. The synthesised compounds were evaluated for their anticonvulsant and CNS depressant properties. Among them, six compounds (IIc, IIg, IIj, IIIc, IIIg, IIIj) exhibited a good activity profile in CNS depressant activity. Five compounds (IIc, IIg, IIj, IIIg, IIIh) showed protection against MES-induced seizures.

CONCLUSION: The Quinazoline derivatives obtained from this research work indicates that the methyl/methoxy group in phenyl ring, amine and thiourea substitution at 3rd position of quinazoline derivatives are essential for CNS depressant activity as well as anticonvulsant activity. Compounds IIc, IIg, IIj, IIIc, IIIg, IIIj and IIhf were found to be a potent compound which may be effective as a potential source for the development of CNS depressant and anti-convulsant drugs with lesser side effects.

KEYWORDS: 7-chloro-2-phenyl-4H-benzo[d][1,3]oxazin-4-one, Quinazoline derivatives, Anticonvulsant activity, CNS depressant activity

INTRODUCTION

Epilepsy is a chronic neurological disorder characterised by unprovoked seizures and affects at least 1 percent (50 million) people worldwide [1, 2]. Anti-convulsants are among the most widely utilised drugs for the treatment of CNS disorders [3]. Both dose related and idiosyncratic adverse effects are relatively common with the existing antiepileptic drugs [4] and this, together with their potential teratogenicity and drug interactions, make long-term use problematical. About one-third of patients do not respond well to current multiple drugs therapy [5]. Currently, no single drug is available which is effective against the various forms and degrees of convulsive disorders [6]. The anti-epileptic drugs mainly act through different mechanisms such as (a) enhancement of gamma amino butyric acid (GABA) mediated inhibition or another effect on the GABA system, (b) modulation of voltage-dependent Na-/Ca+ channels, (c) modulation of synaptic release, (d) inhibition of synaptic excitation mediated by ionotropic glutamate receptors [7]. Several studies reveal that 63% of patients diagnosed and treated seizure-free and more than 50% of epilepsy patients have experienced unwanted side effects [8-10]. Hence, there is a need for safer, more effective anti-epileptic drugs for both generalised and partial seizures. So the search for new anti-epileptic drugs with lower toxicities and fewer side effects than the existing drugs is continuing. Quinazoline derivatives have been focused recently in the design of novel anti-convulsant and CNS depressant agents [11, 12] suggested that the presence of aryl hydrophobic binding site, hydrogen bonding domain and electron donor group regulate the pharmacokinetic properties of the anticonvulsant drug. Fig. 1 shows the pictorial representation of proposed designed quinazoline scaffold which bears the above-mentioned functional groups. The attachment of different functional groups to the quinazoline scaffold gives different structural activity relationship i.e. presence of aromatic/aliphatic group at position 2 and substituted aromatic ring at position 3 are essential for anti-convulsant and CNS depressant activity. As the aromatic ring increases the lipophilicity, the drug can cross the blood-brain barrier. The methyl/methoxy group substitution in the aromatic ring may increase the CNS activity. The introduction of electron withdrawing group at ortho/para position in aromatic ring may increase the CNS activity [13]. So, based on these mentioned hypotheses, the present research work focuses on the following objectives: (a) design and synthesis of some hybrid compounds having above mentioned molecular features, (b) anticonvulsant screening of the synthesised compounds by MES method, (c) CNS depressant screening by forced swimming test method.

In the present study, we also attempt to design and synthesise isomeric new series of quinazoline-4-one/4-thione derivatives based on the pharmacophoric model of CNS activity by structural modifications retaining the essential structural features for the activity and evaluated for their anticonvulsant and CNS depressant properties.

MATERIALS AND METHODS

General

The synthesis of the target compounds was accomplished as illustrated in the fig. 2. The compounds were synthesised according to the procedure given in the respective literature [14-16]. All the reagents and solvents used in the study were of analytical grade purity and procured from Sigma-Aldrich Pvt. Ltd. (India). The progress of the reaction was monitored by thin layer
chromatography with hexane: ethyl acetate (3:2) as the mobile phase and performed on silica gel 60 F254 aluminium sheets (Merck Ltd., Germany); the products were purified by recrystallization. Melting points were determined in open capillaries using a Stuart SMP10 (Barloworld scientific Ltd., UK), electro thermal melting point apparatus. IR spectra were recorded on Shimadzu 8400S FTIR (Shimadzu Corporation, Japan) spectrophotometer using was recorded in cm\(^{-1}\). H NMR (400.13MHz) spectra were acquired on a Bruker Advance II-400 NMR spectrophotometer using tetramethylsilane (TMS) as the internal standard, and the chemical shifts were recorded in \(\delta\). The mass spectrum was obtained on the Finnigan MAT-95 mass spectrometer. Elemental analysis for C, H and N have performed on Perkin Elmer 2400 Series-II CHN analyser.

**Chemical synthesis**

**General procedure**

**Synthesis of 7-chloro-2-phenyl-4H-benzo[d] [1,3] oxazin-4-one (I): (Intermediate)**

4-chloroantranilic acid (0.01 mol) was dissolved in dry pyridine (30 ml) by stirring slowly at room temperature. The solution was cooled to 0 °C and a solution of benzoyl chloride (0.02 mol) in dry pyridine (30 ml) was added slowly with constant stirring. After this addition, the reaction mixture was further stirred for half an hour at room temperature and set aside for 1 hr. The pasty mass obtained was diluted with water (50 ml) and treated with aqueous sodium bicarbonate solution. When the effervescence ceased, the precipitate obtained was filtered off and washed with water, dried and recrystallized from diluted ethanol [14].

**General procedure for the synthesis of compounds, IIa-IIj**

4-chloroantranilic acid (0.01 mol) was dissolved in dry pyridine (30 ml) by stirring slowly at room temperature. The solution was cooled to 0 °C and a solution of benzoyl chloride (0.02 mol) in dry pyridine (30 ml) was added slowly with constant stirring. After this addition, the reaction mixture was further stirred for half an hour at room temperature and set aside for 1 hr. The pasty mass obtained was diluted with water (50 ml) and treated with aqueous sodium bicarbonate solution. When the effervescence ceased, the precipitate obtained was filtered off and washed with water, dried and recrystallized from diluted ethanol [14].

**General procedure for the synthesis of compounds, IIIa-IIIj**

7-chloro-2-phenyl-4H-benzo[d] [1,3] oxazin-4-one (0.01 mol) and phenyl hydrazine (1 mmol, 2.43 g) was heated under reflux in glacial acetic acid. The reaction mixture was allowed to cool at room temperature. The solution was cooled to 0 °C and a solution of benzoyl chloride (0.02 mol) in dry pyridine (30 ml) by stirring slowly at room temperature. The solution was cooled to 0 °C and a solution of benzoyl chloride (0.02 mol) in dry pyridine (30 ml) was added slowly with constant stirring. After this addition, the reaction mixture was further stirred for half an hour at room temperature. The solution was cooled to 0 °C and a solution of benzoyl chloride (0.02 mol) in dry pyridine (30 ml) was added slowly with constant stirring. After this addition, the reaction mixture was further stirred for half an hour at room temperature and set aside for 1 hr. The pasty mass obtained was diluted with water (50 ml) and treated with aqueous sodium bicarbonate solution. When the effervescence ceased, the precipitate obtained was filtered off and washed with water, dried and recrystallized from diluted ethanol[14].

**Compound IIa** (7-chloro-2-phenyl-3-(o-methyl-phenylamino) quinazolin-4 (3H)-one)

Light brown crystalline solid (methanol); 7-chloro-2-phenyl-4H-benzo[d][1,3] oxazin-4-one (0.01 mol) and 2-methyl phenyl hydrazine (0.01 mol) were refluxed for 3 h in presence of glacial acetic acid. The reaction mixture was allowed to cool at room temperature. The crude product was recrystallized using absolute alcohol as light brown crystalline solid. (Yield: 76.7%); m.p 163-166 °C; IR (cm\(^{-1}\)) \(\nu\) C=O (1665.38 cm\(^{-1}\)), \(\nu\) C-Cl (698 cm\(^{-1}\)), \(\nu\) C-H (2911.79 cm\(^{-1}\)), \(\nu\) Ar-CH (3010.02 cm\(^{-1}\)) and \(\nu\) Ar-NH (1592.20 cm\(^{-1}\)).

**Compound IIb** (7-chloro-2-phenyl-3-(p-chloro-phenylamino) quinazolin-4 (3H)-one)

White crystalline solid (methanol); 7-chloro-2-phenyl-4H-benzo[d][1,3] oxazin-4-one (0.01 mol) and 2-chloro phenyl hydrazine (0.01 mol) were refluxed for 3 h in presence of glacial acetic acid. The reaction mixture was allowed to cool at room temperature. The crude product was recrystallized using absolute alcohol as white crystalline solid. (Yield: 76.7%); m.p 163-166 °C; IR (cm\(^{-1}\)) \(\nu\) C=O (1665.77 cm\(^{-1}\)), \(\nu\) C-Cl (698 cm\(^{-1}\)), \(\nu\) C-H (2911.79 cm\(^{-1}\)), \(\nu\) Ar-CH (3010.02 cm\(^{-1}\)) and \(\nu\) Ar-NH (1592.20 cm\(^{-1}\)).

**Compound IIc** (7-chloro-2-phenyl-3-(o-chloro-phenylamino) quinazolin-4 (3H)-one)

Reddish brown solid (methanol); 7-chloro-2-phenyl-4H-benzo[d][1,3] oxazin-4-one (0.01 mol) and o-chloro phenyl hydrazine (0.01 mol) were refluxed for 3 h in presence of glacial acetic acid. The reaction mixture was allowed to cool at room temperature. The crude product was recrystallized using absolute alcohol as reddish brown solid. (Yield: 87.2%); m.p 135-145 °C; IR (cm\(^{-1}\)) \(\nu\) C=O (1751.33 cm\(^{-1}\)), \(\nu\) C-Cl (689.04 cm\(^{-1}\)), \(\nu\) H NMR (400.13MHz) 8:7.49-7.61 (m, 5H, Ar-H), 7.78-8.15 (m, 5H, Ar-H), 7.97-8.23 (t, 6H, Ar-C), 1.06 (s, 1H, N-CH). MS m/z: 361.23 (M+); C14H9ClN2O (Calcd. 343.82); Anal calcld. (%) C, 62.84; H, 3.43; N, 9.85; Found: C, 62.86; H, 3.43; N, 9.85.

**Compound IId** (7-chloro-2-phenyl-3-(o-methyl-phenylamino) quinazolin-4 (3H)-one)

Reddish brown crystalline solid (methanol); 7-chloro-2-phenyl-4H-benzo[d][1,3] oxazin-4-one (0.01 mol) and p-methyl phenyl hydrazine (0.01 mol) were refluxed for 3 h in presence of glacial acetic acid. The reaction mixture was allowed to cool at room temperature. The crude product was recrystallized using absolute alcohol as reddish brown solid. (Yield: 76.7%); m.p 163-166 °C; IR (cm\(^{-1}\)) \(\nu\) C=O (1665.77 cm\(^{-1}\)), \(\nu\) C-Cl (698 cm\(^{-1}\)), \(\nu\) C-H (2911.79 cm\(^{-1}\)), \(\nu\) Ar-CH (3010.02 cm\(^{-1}\)) and \(\nu\) Ar-NH (1592.20 cm\(^{-1}\)).

**Compound IIe** (7-chloro-2-phenyl-3-(p-chloro-phenylamino) quinazolin-4 (3H)-one)

Reddish brown solid (methanol); 7-chloro-2-phenyl-4H-benzo[d][1,3] oxazin-4-one (0.01 mol) and p-chloro phenyl hydrazine (0.01 mol) were refluxed for 3 h in presence of glacial acetic acid. The reaction mixture was allowed to cool at room temperature. The crude product was recrystallized using absolute alcohol as reddish brown solid. (Yield: 76.7%); m.p 163-166 °C; IR (cm\(^{-1}\)) \(\nu\) C=O (1665.77 cm\(^{-1}\)), \(\nu\) C-Cl (698 cm\(^{-1}\)), \(\nu\) C-H (2911.79 cm\(^{-1}\)), \(\nu\) Ar-CH (3010.02 cm\(^{-1}\)) and \(\nu\) Ar-NH (1592.20 cm\(^{-1}\)).

**Compound IIf** (7-chloro-2-phenyl-3-(o-chloro-phenylamino) quinazolin-4 (3H)-one)

Reddish brown crystalline solid (methanol); 7-chloro-2-phenyl-4H-benzo[d][1,3] oxazin-4-one (0.01 mol) and o-chloro phenyl hydrazine (0.01 mol) were refluxed for 3 h in presence of glacial acetic acid. The reaction mixture was allowed to cool at room temperature. The crude product was recrystallized using absolute alcohol as reddish brown solid. (Yield: 76.7%); m.p 163-166 °C; IR (cm\(^{-1}\)) \(\nu\) C=O (1665.77 cm\(^{-1}\)), \(\nu\) C-Cl (698 cm\(^{-1}\)), \(\nu\) C-H (2911.79 cm\(^{-1}\)), \(\nu\) Ar-CH (3010.02 cm\(^{-1}\)) and \(\nu\) Ar-NH (1592.20 cm\(^{-1}\)).
were refluxed for 3 h in presence of glacial acetic acid. The reaction mixture was allowed to cool at room temperature. The crude product was recrystallized using absolute alcohol as brown crystalline solid. (Yield: 80%); m. p. 170-173 °C; IR (cm\(^{-1}\)): \(\nu\) max Ar-CH\(_3\) (3144.98 cm\(^{-1}\)), \(\nu\) (o-chloro-phenylamino) (3310.40 cm\(^{-1}\)), \(\nu\) (m-H, Ar-H) 7.46-7.921 (t, 3H, Ar-H); 4.1 (s, 1H, N-H); 3.78 (s, 1H, Ar-CH\(_3\)); MS, m/z; 272.12 (M\(^+\)); C\(_{10}\)H\(_{12}\)N\(_2\)O (Calcld. 232.23); Anal Calcld. (%) C, 66.42; H, 4.28; N, 11.96.

**Compound IIb** (7-chloro-2-phenyl-3-(p-methoxy-phenylamino)-quinazolin-4 (3H)-thione)

Brownish yellow solid (methanol); 7-chloro-2-phenyl-4H-benzod[1, 3]oxazines-4-one (0.01 mol) and phosphorus pentasulphide (1 mmol, 2.43 g) was heated under reflux in anhydrous xylene (100 ml) for 3 h. The reaction mixture was filtered while hot, the solvent was evaporated and the residue was triturated with dimethyl sulphone (10 ml) and filtered. The clear filtrate was poured into ice water, dried and recrystallized from ethanol to form light brown crystalline solid. (Yield: 67%); m. p. 140-142 °C; IR (cm\(^{-1}\)): \(\nu\) max Ar-CH\(_3\) (3114.98 cm\(^{-1}\)), \(\nu\) (m-H, Ar-H) 7.46-7.921 (t, 3H, Ar-H); 4.1 (s, 1H, N-H); 3.78 (s, 1H, Ar-CH\(_3\)); MS, m/z; 272.12 (M\(^+\)); C\(_{10}\)H\(_{12}\)N\(_2\)O (Calcld. 232.23); Anal Calcld. (%) C, 66.42; H, 4.28; N, 11.96.
Compound III, (3-(4-bromophenylamino)-7-chloro-2-phenylquinazolin-4-(3H)-thione)
Brownish yellow crystalline solid (methanol); A mixture of 7-chloro-2-phenyl-3-(4-bromophenylamino) quinazolin-4-(3H)-one (10 mmol, 2.70 g) and phosphorus penta sulphide (1 mmol, 2.43 g) was heated under reflux in anhydrous xylene (100 ml) for 12 h. The reaction mixture was filtered while hot, the solvent was evaporated and the residue was triturated with dimethyl sulphoxide (10 ml) and filtered. The clear filtrate was poured into ice water, dried and recrystallised from ethanol to form brownish yellow crystalline solid. (Yield: 69%); m. p 162-165 °C; IR (cm⁻¹) νmax Ar-CH₂=NH (3262.75 cm⁻¹), C-N (1152.59 cm⁻¹), C=N (1657.69 cm⁻¹), C-CH₂ (2917.99 cm⁻¹). δ 7.42 (s, 1H, N-H). MS, m/z: 345.12 (M+);
C₇H₆BrClN₂S (Calcld. 393.89); Anal calcd. (%) C, 58.89; H, 3.82; N, 15.05.

Compound III, (7-chloro-2-phenyl-3-(p-nitrophenylamino)quinazolin-4-(3H)-thione)
Reddish brown crystalline solid (methanol); A mixture of 7-chloro-2-phenyl-3-(p-nitrophenylamino) quinazolin-4-(3H)-one (10 mmol, 2.70 g) and phosphorus penta sulphide (1 mmol, 2.43 g) was heated under reflux in anhydrous xylene (100 ml) for 12 h. The reaction mixture was filtered while hot, the solvent was evaporated and the residue was triturated with dimethyl sulphoxide (10 ml) and filtered. The clear filtrate was poured into ice water, dried and recrystallised from ethanol to form reddish brown crystalline solid. (Yield: 70%); m. p 163-165 °C; IR (cm⁻¹) νmax Ar-CH₂=NH (3199.89 cm⁻¹), C-N (1266.56 cm⁻¹), C=N (1671.85 cm⁻¹), N-NH₂ (3027.51 cm⁻¹), C-Cl (692.51 cm⁻¹). δ 7.42 (s, 1H, N-H). MS, m/z: 332.12 (M+);
C₇H₆ClN₂S (Calcld. 346.86); Anal calcd. (%) C, 51.94; H, 3.2; N, 16.15; Found: C, 52.34; H, 3.46; N, 16.55.

Pharmacological activity
The present biological study was approved by the Girijananda Chowdhury Institute of Pharmaceutical Science (GIPS) animal ethical committee (GIPS/IAEC/9). All the chemicals and solvents used for the pharmacological activity were purchased from Sigma-Aldrich. The newly synthesised compounds (IIa-IIIi) were tested for their antiepileptic and CNS depressant activities. The rota-test was performed to assess any probable changes in motor performance, ataxia, loss of skeletal muscle strength and acute neurotoxicity produced by drugs.

Maximum electroshock seizure test
General procedure
Albino mice of either sex, one to two weeks old weighing 20-25 g were used. The food was withdrawn 12-15 h before commencing the experiment while the food was withdrawn immediately before the experiment. The synthesised compounds were suspended in 30% of aqueous solution of polyethylene glycol (PEG 400) and administered to the mice intraperitoneally in a standard volume of 0.5 ml per 20 g body mass at a dose of 30 mg kg⁻¹, 100 mg kg⁻¹, 300 mg kg⁻¹. Reference animals received 30% aqueous PEG 400 and 5, 5 diphenylimidazolidien-2, 4-dione (phenytoin) was used as a reference drug (10 mg kg⁻¹). The maximum seizure was induced by application of an electrical stimulus (50 mA at 60 Hz) for 0.2 s in duration transmitted via corneal electrodes across the brain after 30 min and 4 h following drug administration. After applying the shock, the animals were observed for the type of convulsion produced, and the hind limb extensor response was taken at the endpoint [17-19].

Neurotoxicity study
Rota-rod test
General procedure
The rota-rod test was carried out in accordance with the method described in the literature [20]. The cardinal feature of the test is to ascertain the impairment of motor performance, ataxia, loss of skeletal muscle strength and acute neurotoxicity produced by drugs.
in preclinical studies. Albino mice weighing 20-24 g (n = 4-8), where n represents the number of mice in a group, were trained to balance on the knurled wooden rotating rod (0.032 m diameter) that rotated at 6 min⁻¹. Trained animals were treated with the test compounds at different dose levels (30 mg kg⁻¹, 100 mg kg⁻¹, 300 mg kg⁻¹) administered intraperitoneally. After 30 min and 4 h, respectively, the mice were placed onto the rotating rod for one minute. Neurological impairment was determined as the inability of the animal to remain on the rod for 1 min.

CNS depressant activity

Forced swimming test

General procedure

The synthesised compounds were screened for their CNS depressant activity using Porro et al.'s behavioural despair (forced swimming) test. Male wister rats were placed in a chamber (diameter 0.45 m, height 0.2 m) containing water up to a height 0.15 m at 25 ± 2 °C. Two swim sessions were conducted an initial 15 min test, followed by a 5 min test session 24 h later. The animals were administered (100 mg/kg) the test compound i.p. 30 min before the test session. Then, the mice were dropped individually into the Plexiglas cylinder and left in the water for 5 min. After the first 2 min of the initial vigorous struggling, the animals were immobile. A mouse was judged immobile if it floated in the water in an upright position and made only slight movements in order to prevent sinking. The period of immobility was accounted as passive floating without struggling and making only those movements which were necessary to keep its head above the surface of the water. Changes in the duration of immobilisation were evaluated using one-way analysis of variance (ANOVA) Dunnett’s post hoc graphPad Instant Version 3.01 expressed as means±standard error of the mean (SEM). A p-value of less than 0.05 was considered statistically significant [21].

RESULTS AND DISCUSSION

Physicochemical and spectral characterisation

A novel series of 7-chloro-3-[substituted (amino/phenylamino)]-2-phenyl quinazolin-4 (3H)-one/thione derivatives and 1-(7-chloro-4-oxo/-2-phenyquinazoline-3 (4H-y)) substituted urea derivatives were synthesised as illustrated in the fig 2 and characterised by using TLC, IR, ¹H-NMR and mass spectroscopy. The synthesised compounds were soluble in methanol.

| Table 1: the Preliminary anticonvulsant activity of compounds IIa–IIIj in mice (i.p.) |
|-----------------|-----------------|-----------------|-----------------|
| Compound       | Dose (mg/Kg)   | MES⁺ 30 min  | Toxicity¹ 4h  |
| IIa            | 30             | 0/1           | 0/4            |
|                | 100            | 3/3           | 0/3            |
|                | 300            | 1/1           | 0/1            |
| IIb            | 30             | 0/1           | 0/4            |
|                | 100            | 1/3           | 0/3            |
|                | 300            | 1/1           | 0/1            |
| IIc            | 30             | 1/1           | 0/4            |
|                | 100            | 2/3           | 1/3            |
|                | 300            | 1/1           | 1/1            |
| IId            | 30             | 0/1           | 0/4            |
|                | 100            | 2/3           | 1/3            |
|                | 300            | 1/1           | 1/1            |
| IIf            | 30             | 0/1           | 0/4            |
|                | 100            | 3/3           | 2/3            |
|                | 300            | 1/1           | 1/1            |
| IIg            | 30             | 0/1           | 0/4            |
|                | 100            | 3/3           | 1/3            |
|                | 300            | 0/1           | 0/4            |
| IIf            | 30             | 0/1           | 0/4            |
|                | 100            | 3/3           | 2/3            |
|                | 300            | 1/1           | 1/1            |
| IIh            | 30             | 0/1           | 0/4            |
|                | 100            | 2/3           | 2/3            |
|                | 300            | 1/1           | 1/1            |
| IIi            | 30             | 0/1           | 0/4            |
|                | 100            | 2/3           | 2/3            |
|                | 300            | 1/1           | 1/1            |
| IIIa           | 30             | 0/1           | 0/4            |
|                | 100            | 3/3           | 1/3            |
|                | 300            | 1/1           | 1/4            |
| IIIb           | 30             | 0/1           | 0/4            |
|                | 100            | 2/3           | 1/3            |
|                | 300            | 0/1           | 0/4            |
| IIIc           | 30             | 1/1           | 0/4            |
|                | 100            | 3/3           | 0/3            |
|                | 300            | 0/1           | 1/3            |
| IIId           | 30             | 0/1           | 0/4            |
|                | 100            | 0/3           | 0/3            |
|                | 300            | 0/1           | 2/4            |
| IIIe           | 30             | 0/1           | 0/4            |
|                | 100            | 2/3           | 1/3            |
|                | 300            | 0/1           | 1/4            |
| IIIf           | 30             | 0/1           | 0/4            |
|                | 100            | 0/3           | 0/8            |
The spectral data of compound I shows that Ar-CH\textsubscript{2} absorption width at the range 1752-1598 cm\textsuperscript{-1} which attribute the presence of a ketonic group (C=O) in the quinazoline moiety. Compounds IIa-IIj mainly characterised by the absorption width at the range 1752-15398 cm\textsuperscript{-1} which indicates the presence of (C-H) group in the aromatic ring. The spectral range of 3432-3027 cm\textsuperscript{-1} showed the presence of C=O (1751.33 cm\textsuperscript{-1}), C-Cl (680.72 cm\textsuperscript{-1}), C-N (1592 cm\textsuperscript{-1}), cyclic C-O-C\textsubscript{v} (1060.47 cm\textsuperscript{-1}), C-Cl (680.72 cm\textsuperscript{-1}). The presence of C=O (1751.33 cm\textsuperscript{-1}) which attribute the presence of methyl/methoxy group at 3.46-4.5 ppm for single protons in the \textsuperscript{1}H NMR spectra might be assigned to NH-group. The appearance of singlet proton δ 2.34-2.51 ppm for three protons in its \textsuperscript{1}H NMR spectra which might be assigned to aromatic methyl group confirms the formation of IIc/IIIc. The structures of the compounds are confirmed from the characteristics of the results obtained from analytical techniques.

**Pharmacological activity**

The anticonvulsant activity was evaluated by the MES test and the rota-rod test was used to evaluate neurotoxicity. CNS depressant activity was evaluated by forced swimming test.

**Anticonvulsant activity**

Out of all the compounds evaluated (table-1), IIb, IIc, Ile, IIlc and IIle, exhibited anti-MES activity at either 100 mg kg\textsuperscript{-1} or 300 mg kg\textsuperscript{-1} in 30 min; in addition, IIc and IIlc were also active at 30 mg kg\textsuperscript{-1}. The compounds IIb, IIc, IIe, IIlc, IIle, were more active within 30 min than in 4 h, indicating that they induced rapid onset of the action while III, IIIl, IIj, IIIj elicited late onset of the action.

| Compound\textsuperscript{a} | Substitution | Immobility time(s) | Change from reference (%) |
|-----------------------------|--------------|---------------------|--------------------------|
|                             | (R/R\textsubscript{c}/X) | (mean±SEM)         |                          |
| IIa                         | H            | 175±11.34           | 12.9                     |
| IIb                         | 2-Cl         | 180±10.23           | 16.12                    |
| IIc                         | 2-CH\textsubscript{3} | 236±10.45         | 52.25\textsuperscript{*} |
| II\textsubscript{d}         | 4-Cl         | 192±12.54           | 23.87                    |
| II\textsubscript{e}         | 4-Br         | 198±17.56           | 27.74                    |
| II\textsubscript{f}         | 4-NO\textsubscript{2} | 187±11.19         | 20.64                    |
| II\textsubscript{g}         | 4-OCH\textsubscript{3} | 245±16.12         | 58.06\textsuperscript{*} |
| II\textsubscript{h}         | NH\textsubscript{2} | 192±15.28          | 23.87                    |
| II\textsubscript{i}         | 0            | 212±14.23           | 36.77                    |
| II\textsubscript{j}         | S            | 255±16.78           | 64.51\textsuperscript{*} |
| II\textsubscript{b}         | H            | 178±12.15           | 14.83                    |
| II\textsubscript{b}         | 2-Cl         | 195±13.18           | 25.8                     |
| II\textsubscript{c}         | 2-CH\textsubscript{3} | 261±12.35         | 68.38\textsuperscript{*} |
| II\textsubscript{d}         | 4-Cl         | 188±11.27           | 21.29                    |
| II\textsubscript{e}         | 4-Br         | 191±14.32           | 23.22                    |
| II\textsubscript{f}         | 4-NO\textsubscript{2} | 162±15.75         | 17.41                    |
| II\textsubscript{g}         | 4-OCH\textsubscript{3} | 254±17.05         | 63.87\textsuperscript{*} |
| II\textsubscript{h}         | NH\textsubscript{2} | 212±16.64          | 36.78                    |
| II\textsubscript{i}         | 0            | 210±18.92           | 35.48                    |
| II\textsubscript{j}         | S            | 253±16.01           | 63.22\textsuperscript{*} |
| PEG (control)              | ----         | 155±10.54           | ----                     |
| Carbamazepine\textsuperscript{a} | ----        | 260.6±215.24       | 67.74                    |

\textsuperscript{a} The compounds were tested at a dose of 100 mg kg\textsuperscript{-1} (i. p) or 30 mg kg\textsuperscript{-1} (i. p). \textsuperscript{*} Each value represents the mean±SEM of six rats (n=6) significantly different from the control at p<0.05 (Dunnett’s test).

Mostly, the change in motor coordination was observed for IIb, IIc, IIg, IIl, IIld, IIIg, IIIh at the dose level of 300 mg kg\textsuperscript{-1} Compound Ile, IIg showed good anti-convulsant activity profile may be due to the presence of methyl/methoxy group presence of at 3\textsuperscript{rd} position of 1551.33 cm\textsuperscript{-1}.
phenyl ring in quinazoline ring and compound IIi, IIIi, IIj, IIIj are having electro withdrawing group which probably increases the CNS activity as per the literature survey [13]. Compound IIj showed maximum protection at 30 min and 4 hr which is having thiourea substitution in the ring probably show the anti-epileptic activity and similarly compound IIig elicited increased in activity which may be due to the presence of methoxy group in the para position of phenyl ring which is attached to 3rd position of quinazoline ring. Unlike Compound IIg, Compound IIIh showed moderate protection at 30 min and 4 hr in maximum electro shock seizure which probably show the anti-epileptic activity and similarly compound IIIg elicit increased in activity which may be due to the presence of methoxy group in the para position of phenyl ring which is attached to 3rd position of quinazoline ring. The amine group is an electron donor and increases the hydrogen bonding interaction with the target proteins or receptor for better CNS activity [22]. Finally, it may be concluded that IIc, IIg, IIj, IIIg, IIIh displayed better activity profiles compared with other derivatives as anti-convulsants with a sustained action.

CNS depressant activity

A few of the compounds tested (table 2, fig. 3) were noted as possessing potent CNS depressant properties, especially IIc, IIg, IIj, IIIc, IIIg and IIIj which exhibited remarkable activities revealing the highest duration of immobility comparable to 30 mg/kg of carbamazepine used as reference drug. Compound IIIc elicited excellent CNS depressant activity as compared to the control which may be due to the presence of methyl group in ortho position of phenyl ring which is attached to the 3rd position of quinazoline scaffold. Similarly compound IIg, IIIg is having methoxy group in the phenyl ring. The CNS activity is probably due to the presence of these functional group as cited in the literature [13, 23]. Similar case happened with the compound IIj and IIIj where there is the presence of thiourea group which performed good CNS depressant activity [24]. The structural activity relationship based on the results observed indicated that the type of substituent attached to the N3 of the 7-chloro-(3-substituted phenylamino)-2-phenyl quinazoline-4 (3H)-one scaffold modulated the activity. Attachment of the phenyl group alone does not elicit such favourable activity as compared with the substituted aryl nucleus. Electron withdrawing substituent decrease the activity in descending order, i.e., the higher the electronegativity the lower the activity, whereas the electron releasing substituent appear to be more favourable [25]. The bioisosterically related compounds IIIi, IIIj show similar and potent CNS depressant activity. Rest of the compounds showed mild to moderate CNS depressant activity.

![Fig. 1: Scaffold of the designed quinazoline derivatives](image1)

![Fig. 2: Scheme for the synthesis of 7-chloro-3-[substituted (amino/phenyl amino)]-2-phenyl quinazolin-4 (3H)-one/thione derivatives and 1-[7-chloro-4-oxo]-2-phenylquinazoline-3 (4H-yf)](image2)
CONCLUSION

A series of quinazoline derivatives with a common skeleton were synthesised by replacing different substituted phenyl hydrazine/thiourea derivatives at 3\textsuperscript{rd} position of quinazoline pharmacophore by suitable techniques. The quinazoline derivatives obtained from this research work indicates that the methyl/methoxy group in phenyl hydrazine ring at 3\textsuperscript{rd} position, amine, thiourea substitution at 3\textsuperscript{rd} position of quinazoline derivatives are essential for anti-convulsant and CNS depressant activity. Compounds IIc, IIg, IIj, IIIc, IIIg, IIIj, IIIh were found to be a potent compound which may be effective as a potential source for anti-c onvulsant and CNS depressant activity. Compounds IIc, IIg, IIj, IIIc, IIIg, IIIj, IIIh were found to be a potent compound which may be effective as a potential source for the development of CNS depressant and an anticonvulsant compound having common quinazoline scaffold with lesser side effects. A further study is going on for in vitro study of the newly synthesised and pharmacologically potent quinazoline molecules.

ACKNOWLEDGMENT

The authors acknowledged the assistance of SAIF, North-Eastern Hill University, Shillong, Meghalaya for analytical support regarding spectral analysis.

CONFLICT OF INTERESTS

Declared none

REFERENCES

1. Donner EJ, Snead OC. New generation anticonvulsants for the treatment of epilepsy in children. J Am Soc Exp Neuro Ther 2006;3:170-80.
2. Mahendra RS, Mangesh G, Kailash GB, Shashikant VB, Ana N Kalyan CA, Nisheeth CD, et al. Synthesis and anticonvulsant activity of clamped thiazolidine-barbituric acid and thiazolidine-triazole derivatives. ARKIVOC 2007;NV:58-74.
3. Mochizuki D, Sontanin and noradrenaline reuptake inhibitors in animal models of pain. Human Psychopharmacol 2004;19:515-S19.
4. Brodie MJ. Established anticonvulsants and treatment of refractory epilepsy. Lancet 1990;3:36:350-4.
5. Schmidt D, Lösch W. Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms. Epilepsia 2005;46:858-77.
6. Kwan P, Brodie MJ. Early identification of refractory epilepsy. New Engl J Med 2000;342:314-9.
7. Pollard JR, French J. Antiepileptic drugs in development. Lancet Neurol 2006;5:1064-7.
8. Dichter MA, Brodie MJ. New antiepileptic drugs. New Engl J Med 1996;334:1583-90.
9. Brodie MJ, Dichter MA. Antiepileptic drugs. New Engl J Med 1996;334:168-75.
10. Kwan P, Brodie MJ. Drug treatment of epilepsy: when does it fail and how to optimize its use? CNS Spectr 2004;9:110-9.
11. Siddqui N, Akhtar JM, Ali R, Azaad B. An updated review: emerging anticonvulsants. Int J Pharm Biosci Arch 2010;1:104-15.
12. Dimsmock JR, Pandeya SN, Quail JW, Pugazhenthhi U, Allen TM, Kao GY, et al. Evaluation of the semicarbazones, thiosemicarbazones and bis-carbohydrazones of some aryl alicyclic ketones for anticonvulsant and other biological activities. Eur J Med Chem 1995;30:303-14.
13. Mahato AK, Srivastava B, Nithya SC. Chemistry, structure activity relationship and biological activity of quinazolin-4-(3H)-one derivatives. Inventi Rapid Med Chem 2011;2:400-2.
14. Klangovan P, Ganguy S, Pandit V. Design and synthesis of novel quinazoline derivatives as broad spectrum anticonvulsant and antimicrobial agent. J Pharm Res 2010;3:703-6.
15. Hemlata K, Girija K. Synthesis of some novel 2,3disubstituted quinazoline derivatives as analgesic and anti-inflammatory agents. Int J Pharm Sci 2013;1:103-6.
16. Adel S, Azaab E, Mohamed A, Omar A, Alka AM, Naglaa I, et al. Design, synthesis and biological evaluation of novel quinazoline derivatives as potential antitumor agents: molecular docking study. Eur J Med Chem 2010;45:188-98.
17. Kral RL, Penry JK, White BG, Kuiperberg HJ, Swinyard EA. Antiepileptic drug development: II. Anticonvulsant drug screening. Epilepsia 1978;19:409-28.
18. Porter RJ, Cereghino JJ, Gladding GD, Hessie BJ, Kuiperberg HJ, Scoville B, et al. Antiepileptic drug development program. Cleveland Clin Quart 1984;5:293–305.
19. Ladda PL. Screening of Ricinus communis Linn. Leaves for anticonvulsant and analgesic activity. Asian J Pharm Clin Res 2014;7:110-4.
20. Rajak H, Desmukh R, Aggarwal N, Kashaw S, kharya MD, Mishra P, et al. Synthesis of novel 2,5-disubstituted 1,3,4-thiadiazoles for their potential anticonvulsant activity: pharmacophoric model studies. Arch Pharm 2009;342:453.
21. Porsolt RD, Anton G, Blanet N, Jalbre M. Behavioral despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharm Pharmacol 1978;47:379-91.
22. Ibrahim MK, El-Adl K, Al-Karmalawy AA. Design, synthesis, molecular docking and anticonvulsant evaluation of novel 6ido-2-phenyl-3-substituted-quinazolin-4(3H)-ones. Bull Faculty Pharm Cairo University 2015;5:53:101-16.
23. Adel S, Kamal EH. Design and synthesis of novel 7-amino Quinazoline derivatives: antitumor and anticonvulsant activities. Bioorg Med Chem Lett 2012;22:1879-85.
24. Kashaw SK, Kashaw V, Mishra P, Jain NK. Design, synthesis and potential CNS activity of some novel 1-(4-substituted-phenyl)-3-(4-oxo-2-propyl-4H-quinazolin-3-yl)-urea. ARKIVOC 2008;IV:17-26.
25. Kashaw SK, Kashaw V, Mishra P, Jain NK, Stable JP. Synthesis, anticonvulsant and CNS depressant activity of some new bioactive 1-(4-substituted-phenyl)-3-(4-oxo-2-phenyl-ethyl-4H-quinazolin-3-yl)-urea. Eur J Med Chem 2009;44:4335-43.

How to cite this article

- Biswajit Dash, Suvakantara Dash, Damiki Laloo. Design and synthesis of 4-substituted quinazoline derivatives for their anticonvulsant AND CNS depressant activities. Int J Pharm Sci 2017;9(1):165-172.